Pyxis Oncology, Inc. 8-K

What Happened

• On March 23, 2026, Pyxis Oncology, Inc. (PYXS) announced its financial results for the full year ended December 31, 2025 via a press release and provided a corporate update. The press release and the updated corporate presentation were made available as exhibits to the Current Report on Form 8-K.

Key Details

• Date filed: March 23, 2026. Reporting period: full year ended December 31, 2025.
• Press release announcing results furnished as Exhibit 99.1; updated corporate presentation furnished as Exhibit 99.2.
• The company posted the corporate presentation on its website for investor access.
• The 8-K was signed by Jitendra Wadhane, Principal Financial and Accounting Officer. The furnished materials are stated as not “filed” for purposes of Section 18 of the Exchange Act.

Why It Matters

• This 8-K signals that Pyxis released its FY2025 earnings and related corporate information; investors should review the press release and presentation for key metrics such as revenue, net loss, cash position, guidance, and any program or strategy updates.
• The updated corporate presentation may include refreshed details on the company’s pipeline, milestones, or go‑forward strategy that could affect valuation or near‑term catalysts.
• Because the materials are furnished (not “filed”), they are less subject to Section 18 liability; nonetheless, they are the primary source for the company’s reported FY2025 financial results and investor guidance.